Using COVID-19 vaccines in patients with anticoagulation and bleeding disorders

7 January 2021Information on use of the vaccine in patients who are receiving anticoagulants or have a bleeding disorder is given below.

Consultations (counselling) about oral anticoagulants apixaban, dabigatran, edoxaban, rivaroxaban and warfarin for patients with aphasia

8 October 2020These resources are designed to support all clinicians who communicate with patients prescribed warfarin  or direct oral anticoagulants (DOACs), formerly known as novel  oral anticoagulants…

Suggestions for Therapeutic Drug Monitoring in Adults in Primary Care

29 September 2020This document is intended to support local discussions on how to monitor commonly prescribed high risk medicines in primary care.    The monitoring parameters cited…

Safety in Lactation: Drugs for thromboembolic disorders

18 September 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Oral anticoagulants The coumarin anticoagulants, warfarin…

Anticoagulation for Atrial Fibrillation ‘Perfect’

26 May 2020Anticoagulation is key to reducing the risk of stroke in atrial fibrillation (AF).  However ensuring that the anticoagulant is prescribed at the correct dose for…
Search Articles

Medicine Compliance Aid Stability

EliquisBristol-Myers Squibb-Pfizer

Bristol-Myers Squibb-Pfizer
Tablets f/c 2.5mg
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage.
9 November 2015

Lactation Safety Information

Direct activated factor X inhibitor
No published evidence of safety
20 October 2016